Pat Lawman, PHD

Prior to co-founding Morphogenesis, Dr. Lawman was a Senior Research Scientist and Division Director of Cancer Molecular Biology at the WDMCI, where she initiated and coordinated the multifaceted molecular biology, gene targeting, gene therapy, gene delivery, and universal stem cell programs. Prior to joining the WDMCI, she served as a Postdoctoral Fellow in Hematology and Oncology at Univ. of FL. Dr. Lawman also received masters and PhD degrees from the Univ. of FL. She is a co-inventor on over 30 issued patents and a number of pending applications on subjects ranging from stem cell growth factors, monoclonal antibodies, intelligent materials, cancer immunotherapies and the replacement of histocompatibility antigens for transplantation. Dr. Lawman is also co-editor of the authoritative volume, Cancer Vaccines: Methods and Protocols, Humana Press/Springer Verlag. As CEO, Dr. Lawman has taken Morphogenesis from an R&D company to a multi-product clinical stage concern.